Home Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome
Article
Licensed
Unlicensed Requires Authentication

Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome

  • Sandra Huber da Silva , Renata da Silva Pereira , Bruna dos Santos Hausen , Cristiane Signor , Patrícia Gomes , Marli Matiko Anraku de Campos and Rafael Noal Moresco EMAIL logo
Published/Copyright: December 14, 2010

Abstract

Background: Myocardial ischemia may alter the metal binding capacity of circulating serum albumin. Thus, the aim of this study was to describe an automated method to measure ischemia-induced alterations in the binding capacity of serum albumin for exogenous nickel, and to evaluate the diagnostic characteristics of this assay for the assessment of acute coronary syndrome (ACS) in patients presenting to the emergency room (ER) with acute chest pain.

Methods: We assessed the concentrations of cardiac troponin I (cTnI), serum albumin, ischemia-modified albumin (IMA) measured by the cobalt-albumin binding assay (CABA), and by an automated nickel-albumin binding assay (NABA) in the following groups: ACS (n=63) and non-ischemic chest pain (NICP, n=26). Biochemical markers were determined in blood samples obtained from patients within 3 h of ER admission.

Results: cTnI, CABA and NABA concentrations were higher in ACS group in comparison to the NICP group. A significant correlation between NABA and CABA was observed (r=0.5387, p<0.001). Areas under the curve for CABA and NABA were 0.7289 and 0.7582, respectively. Both CABA and NABA have the ability to discriminate patients with ACS. However, NABA has a slightly higher ability to discriminate ACS compared with CABA.

Conclusions: Patients with ACS have reduced nickel binding to human serum albumin, and NABA may have an important role as an early marker of myocardial ischemia, particularly in patients presenting to the ER with acute chest pain.


Corresponding author: Rafael Noal Moresco, Universidade Federal de Santa Maria, Centro de Ciências da Saúde, Departamento de Análises Clínicas e Toxicológicas, Avenida Roraima 1000, Prédio 26, Sala 1402 Camobi, 97105-900, Santa Maria-RS, Brazil Phone: +55 55 32208941, Fax: +55 55 32208018

Received: 2010-5-28
Accepted: 2010;-9-16
Published Online: 2010-12-14
Published in Print: 2011-03-01

©2011 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Biomarkers of neurodegenerative diseases
  3. Reviews
  4. CSF biomarkers in neurodegenerative diseases
  5. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
  6. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
  7. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
  8. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease
  9. Parkinson's disease – the continuing search for biomarkers
  10. α-Synuclein in Parkinson disease and other neurodegenerative disorders
  11. S100B protein in neurodegenerative disorders
  12. Inflammatory and structural biomarkers in acute traumatic spinal cord injury
  13. Homocysteine: a biomarker in neurodegenerative diseases
  14. Editorial
  15. ROMA or death: advances in epithelial ovarian cancer diagnosis
  16. Review
  17. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays
  18. General Clinical Chemistry and Laboratory Medicine
  19. Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years’ experience using the Six Sigma concept
  20. Determination of oxidative and occupational stress in palliative care workers
  21. Effect of cigarette smoking on plasma homocysteine concentrations
  22. Erythrocyte membrane protein analysis by sodium dodecyl sulphate-capillary gel electrophoresis in the diagnosis of hereditary spherocytosis
  23. Evaluation of hematological parameters on admission for the prediction of 7-day in-hospital mortality in a large trauma cohort
  24. Platelet function testing in hirudin and BAPA anticoagulated blood
  25. Evaluation of the iChem® Velocity™ Urine Chemistry Analyzer in a hospital routine laboratory
  26. Crystalluria: prevalence, different types of crystals and the role of infrared spectroscopy
  27. Cancer Diagnostics
  28. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
  29. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population
  30. Cardiovascular Diseases
  31. APOA5 −1131T/C polymorphism is associated with coronary artery disease in a Chinese population: a meta-analysis
  32. Assessment of the nickel-albumin binding assay for diagnosis of acute coronary syndrome
  33. Letters to the Editor
  34. AGER gene -374T>A (rs1800624) polymorphism is not associated with the severity of non-diabetic coronary artery disease in Han Chinese
  35. Some lessons learned from using medium scale genotyping techniques in pharmacogenetic research
  36. Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice
  37. Cross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples
  38. Modulated human maternal and premature neonatal erythrocyte membrane enzyme activities in relation to the mode of delivery: in vitro restoration with L-Carnitine
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.063/html
Scroll to top button